Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2018
Filed with the SEC on Mar 29, 2019 and accepted by EDGAR at Mar 29, 2019, 16:28 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2018-01-01 to 2018-12-31 | $6.1m | us-gaap:ResearchAndDevelopmentExpense |
| Income tax | 12 months2018-01-01 to 2018-12-31 | $4.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Current assets | At period end2018-12-31 | $7.9m | ifrs-full:CurrentAssets |
| Total assets | At period end2018-12-31 | $8.0m | ifrs-full:Assets |
| Current liabilities | At period end2018-12-31 | $3.1m | ifrs-full:CurrentLiabilities |
| Shares outstanding | At period end2018-12-31 | 40,399,290 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-19-005251. Last ingested by Listed: Nov 2, 2026, 07:04 ET. Listed shows no prices and gives no investment advice.